Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines.

abstract：:The present study seeks to establish a relationship between the quality of a surgical procedure and the subsequent hospital costs for that procedure by investigating the influence of both patient and peri-operative factors on the hospital costs of radical prostatectomy. All men who underwent radical prostatectomy at o...

journal_title：Prostate cancer and prostatic diseases

authors： Benoit RM,Cohen JK

更新日期：2001-01-01 00:00:00

abstract：BACKGROUND:Intermittent androgen deprivation (IAD) for prostate cancer was studied with the objective of reducing the side effects of treatment and potentially delaying the development of hormone resistance. There also appears to be a quality of life benefit during off-treatment intervals owing to the recovery of serum...

journal_title：Prostate cancer and prostatic diseases

authors： Tunn UW,Canepa G,Kochanowsky A,Kienle E

更新日期：2012-09-01 00:00:00

abstract：:Rectum and bladder are the crucial organs at risk for curative radiation therapy of localized prostate cancer. We analyzed the incidence, profile and time course of late rectal radiation toxicity. A total of 320 patients with T1-3 prostate cancer were treated with three-dimensional conformal radiation therapy (3D-CRT)...

journal_title：Prostate cancer and prostatic diseases

authors： Odrazka K,Dolezel M,Vanasek J,Vaculikova M,Zouhar M,Sefrova J,Paluska P,Vosmik M,Kohlova T,Kolarova I,Macingova Z,Navratil P,Brodak M,Prosvic P

更新日期：2010-06-01 00:00:00

abstract：BACKGROUND:Oral antiandrogen therapies are predominantly used in older men, but real-life studies evaluating the impact of age on pharmacokinetic exposure are lacking. This study aims to evaluate the impact of age on the pharmacokinetic profiles of abiraterone acetate and enzalutamide in clinical practice. PATIENTS AN...

journal_title：Prostate cancer and prostatic diseases

authors： Crombag MBS,van Nuland M,Bergman AM,Rosing H,Schellens JHM,Huitema ADR,Beijnen JH

更新日期：2019-03-01 00:00:00

abstract：:To examine the difference in Prostate Specific Antigen (PSA)-Relapse Free Survival (RFS) in patients (pts) with prostate cancer treated with permanent prostate brachytherapy (PPB) alone (monotherapy) or combined modality PPB and external radiotherapy (CMT) by a matched pair analysis. There were 1476 pts who were treat...

journal_title：Prostate cancer and prostatic diseases

authors： Potters L,Fearn P,Kattan M

更新日期：2002-01-01 00:00:00

abstract：INTRODUCTION:Approximately 85% of patients who die from prostate cancer present the spread of bone metastases. Even though the radiological appearance of such metastases is osteoblastic, it is now known that these lesions coexist in their microenvironment with blastic and lytic lesions. The process always begins with b...

journal_title：Prostate cancer and prostatic diseases

authors： Rodrigues P,Hering F,Campagnari JC

更新日期：2004-01-01 00:00:00

abstract：:An increased molecular understanding of localized prostate cancer and the improved ability for molecular testing of pathologic tissue has led to the development of multiple clinical assays. Here we review the relevant molecular biology of localized prostate cancer, currently available tissue-based tests and describe w...

journal_title：Prostate cancer and prostatic diseases

authors： Ross AE,D'Amico AV,Freedland SJ

更新日期：2016-03-01 00:00:00

abstract：BACKGROUD:The European Organization for Research and Treatment of Cancer (EORTC) trial 22,911 reported 74% 5-year biochemical disease-free survival (bDFS) in patients with prostate carcinoma treated with radical prostatectomy (RP) followed by postoperative radiotherapy (RT). This study aimed to improve these outcomes b...

journal_title：Prostate cancer and prostatic diseases

authors： Mantini G,Siepe G,Alitto AR,Buwenge M,Nguyen NP,Farioli A,Schiavina R,Catucci F,Deodato F,Fionda B,Frascino V,Macchia G,Ntreta M,Padula GDA,Arcelli A,Cammelli S,Rambaldi GZ,Cilla S,Valentini V,Morganti AG

更新日期：2018-11-01 00:00:00

abstract：:The purpose of this study was to evaluate the relationship of baseline body mass index (BMI) and serum testosterone level with prostate cancer outcomes in men with castration-resistant metastatic prostate cancer (CRPC). BMI and testosterone levels were evaluated for their ability to predict overall survival (OS) and p...

journal_title：Prostate cancer and prostatic diseases

authors： Armstrong AJ,Halabi S,de Wit R,Tannock IF,Eisenberger M

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common problem with unclear etiology. Some diet and lifestyle factors were thought to correlate with CP/CPPS, but studies comprehensively investigate this correlation are rarely available. The current study was conducted to determine the potenti...

journal_title：Prostate cancer and prostatic diseases

authors： Chen X,Hu C,Peng Y,Lu J,Yang NQ,Chen L,Zhang GQ,Tang LK,Dai JC

更新日期：2016-03-01 00:00:00

abstract：:Men with diabetes mellitus are less likely to be diagnosed with prostate cancer (PCa). As diabetic men have lower serum PSA, it is unclear if this is due to lower PCa incidence or reflects detection bias from fewer PSA-triggered biopsies. To account for differential biopsy rates, we used multivariate regression to exa...

journal_title：Prostate cancer and prostatic diseases

authors： Wu C,Moreira DM,Gerber L,Rittmaster RS,Andriole GL,Freedland SJ

更新日期：2011-12-01 00:00:00

abstract：:The role of neoadjuvant androgen deprivation (NAD) in high-risk prostate cancer patients receiving high-dose radiotherapy (RT) remains unstudied. To evaluate the effect of a course of NAD, we reviewed the experiences of three institutions treating these patients with combined RT and high-dose rate brachytherapy (HDR)....

journal_title：Prostate cancer and prostatic diseases

authors： Vargas C,Martínez A,Galalae R,Demanes J,Harsolia A,Schour L,Nuernberg N,Gonzalez J

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:CYR61 (cysteine-rich protein 61, also named IGFBP10) is a secreted signaling molecule that promotes angiogenesis and tumor growth. The goal of this study is to determine whether a functional polymorphism in the promoter region of the CYR61 gene (rs3753793) is associated with prostate cancer (PCa) risk and ge...

journal_title：Prostate cancer and prostatic diseases

authors： Tao L,Chen J,Zhou H,Qin C,Li P,Cao Q,Li J,Ju X,Zhu C,Wang M,Zhang Z,Shao P,Yin C

更新日期：2013-03-01 00:00:00

abstract：OBJECTIVE:To survey UK urologists and radiation oncologists in the evaluation and treatment of localised prostate cancer in the adjuvant and salvage setting. METHODS:Postal questionnaires were mailed to 292 urologists and 98 radiation oncologists in the UK. RESULTS:In all, 188 (48%) questionnaires were returned. In t...

journal_title：Prostate cancer and prostatic diseases

authors： Lee LW,Clarke NW,Ramani VA,Cowan RA,Wylie JP,Logue JP

更新日期：2005-01-01 00:00:00

abstract：:Prostate cancer is the commonest non-skin malignancy in the United States and has a substantial mortality rate despite the use of PSA-based screening. Furthermore, therapy for prostate cancer by surgery, radiotherapy or hormonal manipulation carries a significant risk of treatment-related morbidity. Recent analysis of...

journal_title：Prostate cancer and prostatic diseases

authors： Klein EA,Thompson IM,Lippman SM,Goodman PJ,Albanes D,Taylor PR,Coltman C

更新日期：2000-11-01 00:00:00

abstract：OBJECTIVES:To assess the efficacy of high-intensity interval training (HIIT) for improving cardiorespiratory fitness (CRF) in patients awaiting resection for urological malignancy within four weeks. SUBJECTS/PATIENTS AND METHODS:A randomised control trial of consecutive patients aged (>65 years) scheduled for major ur...

journal_title：Prostate cancer and prostatic diseases

authors： Blackwell JEM,Doleman B,Boereboom CL,Morton A,Williams S,Atherton P,Smith K,Williams JP,Phillips BE,Lund JN

更新日期：2020-12-01 00:00:00

abstract：:This session included five presentations in the areas of pathology of precursor lesions and carcinoma of the prostate, the value of determining neovascularity in the diagnosis and staging of prostate cancer, new 'molecular' markers, correlation between pre- and postoperative Gleason scores and a study dealing with tra...

journal_title：Prostate cancer and prostatic diseases

authors： Sakr WA,Brawer MK,Moul JW,Donohue R,Schulman CG,Sakr D

更新日期：1999-01-01 00:00:00

abstract：:This corrects the article DOI: 10.1038/pcan.2017.5. ...

journal_title：Prostate cancer and prostatic diseases

authors： Weiner AB,Matulewicz RS,Schaeffer EM,Liauw SL,Feinglass JM,Eggener SE

更新日期：2017-12-01 00:00:00

abstract：PURPOSES:To address prostate cancer (PCa) detection with respect to the number of biopsy sessions performed, to identify risk factors for detection after a negative biopsy, and to analyze the clinical characteristics of the detected tumors. SCOPE:Only biopsied men (sextant) were included. A total of 1011 biopsy sessio...

journal_title：Prostate cancer and prostatic diseases

authors： Lujan M,Paez A,Santonja C,Pascual T,Fernandez I,Berenguer A

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:Emerging data suggest that obesity increases the risk of aggressive prostate cancer (PC), but the mechanisms underlying this relationship remain to be fully elucidated. Oxidative stress (OS) is a key process in the development and progression of PC. Adiponectin, an adipocyte-specific hormone, circulates at r...

journal_title：Prostate cancer and prostatic diseases

authors： Lu JP,Hou ZF,Duivenvoorden WC,Whelan K,Honig A,Pinthus JH

更新日期：2012-03-01 00:00:00

abstract：BACKGROUND:Prostate cancer (PCa) is characterized as the most frequent type of cancer in males. Recent research has suggested patients who have diabetes mellitus taking metformin (MF) have a lower risk of PCa. MF has antineoplastic effects such as adenosine monophosphate-activated protein kinase (AMPK)-dependent and in...

journal_title：Prostate cancer and prostatic diseases

authors： Zaidi S,Gandhi J,Joshi G,Smith NL,Khan SA

更新日期：2019-09-01 00:00:00

abstract：:Radiofrequency interstitial tumor ablation (RITA) is a thermal ablation method that uses needles and low radiofrequency (RF) energy. The aim of our study was to evaluate the histopathology of thermal lesions induced by RF energy delivered interstitially in prostate cancer patients who subsequently underwent prostatect...

journal_title：Prostate cancer and prostatic diseases

authors： Patriarca C,Bergamaschi F,Gazzano G,Corrada P,Ordesi G,Zanitzer L,Di Pasquale M,Giunta P,Campo B

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS:Prostate cancer patients consecutively treated with definitive radiation at our institution by a single provi...

journal_title：Prostate cancer and prostatic diseases

authors： Narang AK,Trieu J,Radwan N,Ram A,Robertson SP,He P,Gergis C,Griffith E,Singh H,DeWeese TA,Honig S,Annadanam A,Greco S,DeVille C,McNutt T,DeWeese TL,Song DY,Tran PT

更新日期：2017-06-01 00:00:00

abstract：:Prostate cancer patients' management demands prioritization, adjustments, and a tailored approach during the unprecedented SARS-CoV-2 pandemic. Benefit of care from treatment must be carefully weighed against the potential of infection and morbidity from COVID-19. Furthermore, urologists need to be cognizant of their ...

journal_title：Prostate cancer and prostatic diseases

authors： Obek C,Doganca T,Argun OB,Kural AR

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:Agent Orange (AO) was previously identified as a significant risk factor for biochemical recurrence (BCR) after radical prostatectomy (RP) in prostate cancer patients. In this study, we determined the levels of dioxin biological toxicity using toxic equivalency (TEQ) values and examined the impact of dioxin-...

journal_title：Prostate cancer and prostatic diseases

authors： Li Q,Lan L,Klaassen Z,Shah SR,Moses KA,Terris MK

更新日期：2013-12-01 00:00:00

abstract：:Androgen deprivation therapy improves survival of patients with prostate cancer and leads to hypogonadal state. Gonadal hormones are essential for skeletal integrity and hypogonadism constitutes a major risk factor for osteoporosis. To examine the bone loss secondary to androgen deprivation therapy, we reviewed the bo...

journal_title：Prostate cancer and prostatic diseases

authors： Yaturu S,DjeDjos S,Alferos G,Deprisco C

更新日期：2006-01-01 00:00:00

abstract：:Increasingly animal and clinical studies suggest that intermittent therapy may improve the duration of hormone dependence in patients with prostate cancer. However there remains uncertainty as to optimal duration of treatment and level of prostate-specific antigen (PSA) before treatment is restarted. The aim of this s...

journal_title：Prostate cancer and prostatic diseases

authors： Oliver RT,Farrugia D,Ansell W,Williams G,Chinegwundoh F

更新日期：2000-12-01 00:00:00

abstract：:Prescription sales of testosterone have risen considerably over the last decade and are likely to continue to grow as further preparations become available. Testosterone promotes existing prostate cancer; however, concern does exist as to whether or not testosterone therapy induces prostate cancer. The aim of this art...

journal_title：Prostate cancer and prostatic diseases

authors： Gould DC,Kirby RS

更新日期：2006-01-01 00:00:00

abstract：INTRODUCTION:Treatment options for lymph node positive prostate cancer are limited. We retrospectively compared patients who underwent external radiotherapy (ERT) to patients treated by radical prostatectomy (RPX). MATERIALS AND METHODS:A total of 102 lymph node positive patients from the RPX series at Ulm University ...

journal_title：Prostate cancer and prostatic diseases

authors： Kuefer R,Volkmer BG,Loeffler M,Shen RL,Kempf L,Merseburger AS,Gschwend JE,Hautmann RE,Sandler HM,Rubin MA

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:The value of radical prostatectomy (RP) as an approach for very high-risk prostate cancer (PCa) patients is controversial. To examine the risk of 10-year cancer-specific mortality (CSM) and other-cause mortality (OCM) according to clinical and pathological characteristics of very high-risk cT3b/4 PCa patient...

journal_title：Prostate cancer and prostatic diseases

authors： Moltzahn F,Karnes J,Gontero P,Kneitz B,Tombal B,Bader P,Briganti A,Montorsi F,Van Poppel H,Joniau S,Spahn M

更新日期：2015-03-01 00:00:00